Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
34
days
Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis
AuthorsK. E. Blethen; C. P. Wolford; G. L. Pecar; T. A. Arsiwala; E. Adjeroh; L. P. Dykstra; B. N. Kielkowski; P. R. Lockman
Affiliations1. Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, USA; 2. Rockefeller Neuroscience Institute, West Virginia University, Morgantown, USA
134
days
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma
AuthorsFeihua Chen; Mouchun Gong; Dengcheng Weng; Zhaoqing Jin; Guofeng Han; Ziqiang Yang; Junjun Han; Jianjiang Wang
Affiliations1. Department of General Surgery, Hangzhou Medical College Affiliated Lin’an People’s Hospital, Hangzhou, China
34
days
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
AuthorsJoanna Baginska; Allison Nau; Ilana Gomez Diaz; Anita Giobbie-Hurder; Jason Weirather; Juliana Vergara; Charlotte Abrecht; Margaret Hallisey; Jenna Dennis; Mariano Severgnini; Julia Huezo; Isabella Marciello; Osama Rahma; Michael Manos; Andrew S. Brohl; Philippe L. Bedard; Daniel J. Renouf; Elad Sharon; Howard Streicher; Patrick A. Ott; Elizabeth I. Buchbinder; F. Stephen Hodi
Affiliations1. Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA; 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA; 3. Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA; 4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; 5. Cancer and Department of Medicine, University of British Columbia, Vancouver, Canada; 6. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
35
days
Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
AuthorsAkashdip Singh; Eline T. A. M. Mommers-Elshof; Saskia V. Vijver; J. H. Marco Jansen; Susanne Gonder; Robert Jan Lebbink; Dominique Bihan; Richard W. Farndale; Louis Boon; Solomon Langermann; Jeanette H. W. Leusen; Dallas Flies; Linde Meyaard; M. Ines Pascoal Ramos
Affiliations1. Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands; 2. Oncode Institute, Utrecht, The Netherlands; 3. Department of Biochemistry, University of Cambridge, Cambridge, UK; 4. JJP Biologics, Warsaw, Poland; 5. Nextcure, Beltsville, USA
39
days
Vaccination against neoantigens induced in cross-priming cDC1 in vivo
AuthorsEmily S. Clark; Ana Paula Benaduce; Wasif N. Khan; Olivier Martinez; Eli Gilboa
Affiliations1. Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, USA; 2. Department of Biological Sciences, Florida International University, Miami, USA; 3. Mnemo Therapeutics, Paris, France; 4. Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, USA
45
days
Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases
AuthorsCeline Man Ying Li; Yoko Tomita; Bimala Dhakal; Teresa Tin; Runhao Li; Josephine A. Wright; Laura Vrbanac; Susan L. Woods; Paul Drew; Timothy Price; Eric Smith; Guy J. Maddern; Kevin Fenix
Affiliations1. Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, Australia; 2. The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia; 3. Medical Oncology, The Queen Elizabeth Hospital, The University of Adelaide, Adelaide, Australia; 4. Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, Australia; 5. Department of Medical Specialties, Adelaide Medical School, The University of Adelaide, Adelaide, Australia
46
days
Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53
AuthorsBrendan L. C. Kinney; Sreenivasulu Gunti; Vikash Kansal; Connor J. Parrish; Nabil F. Saba; Yong Teng; Mary Katherine Henry; Fang-Yi Su; Gabriel A. Kwong; Nicole C. Schmitt
Affiliations1. Department of Otolaryngology – Head and Neck Surgery, Head and Neck Cancer Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA; 2. Winship Cancer Institute, Emory University, Atlanta, USA; 3. National Institute of Deafness and Communication Disorders, NIH, Bethesda, USA; 4. Saint Louis University School of Medicine, St. Louis, USA; 5. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA; 6. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory School of Medicine, Atlanta, USA; 7. Emory University School of Medicine, Atlanta, USA
108
days
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
AuthorsXinfeng Chen; Binghe Tan; Haizhou Xing; Xuan Zhao; Yu Ping; Zhen Zhang; Jianmin Huang; Xiujuan Shi; Na Zhang; Boxu Lin; Weijie Cao; Xin Li; Xudong Zhang; Ling Li; Zhongxing Jiang; Mingzhi Zhang; Wei Li; Mingyao Liu; Bing Du; Yi Zhang
Affiliations1. Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2. Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 3. Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China; 4. BRL Medicine Inc, Shanghai, China; 5. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 6. State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, China; 7. School of Life Sciences, Zhengzhou University, Zhengzhou, China; 8. Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou, China
132
days
Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells
AuthorsLibao Liu; Laurie Rangan; Nathan Vanalken; Qianqian Kong; Susan Schlenner; Steven De Jonghe; Dominique Schols; Tom Van Loy
Affiliations1. Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium; 2. Laboratory of Adaptive Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
82
days
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors
AuthorsM Costa-Garcia; JJ Rojas; MD Ramos; P Barlabé; P Calvo; J Navas; R Alemany; R Moreno
Affiliations1. Cancer Immunotherapy Group, Oncobell and iProCURE programs, IDIBELL-Institut Català d’Oncologia, l’Hospitalet de Llobregat, Barcelona, Spain; 2. Immunology Unit, Department of Pathology and Experimental Therapies, School of Medicine, University of Barcelona-UB, Barcelona, Spain; 3. Immunity, Inflammation, and Cancer Group, Oncobell program, Institut d’Investigació Biomèdica de Bellvitge-IDIBELL, l’Hospitalet de Llobregat, Barcelona, Spain; 4. Program of Regenerative Medicine, Centre for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Pamplona, Spain
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days